<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Prognosis of acquired <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>)-related non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> has improved since the introduction of highly active antiretroviral therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e>) still have poor outcome in patients with bone marrow (BM) or central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) involvement when treated with standard-dose chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>We have prospectively evaluated the LMB86 regimen in 63 human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus (HIV)-infected patients with stage IV (BM and/or <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> consecutively recruited between November 1992 and January 2006 </plain></SENT>
<SENT sid="3" pm="."><plain>At <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> diagnosis, the median CD4 cell count was 239 x 10(6)/L (range, 16-1188 x 10(6)/L) </plain></SENT>
<SENT sid="4" pm="."><plain>BM and <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement were present in 55 (80%) and 48 (76%) patients, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Forty-four patients (70%) achieved complete response </plain></SENT>
<SENT sid="6" pm="."><plain>Seven treatment-related <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred and <z:hpo ids='HP_0000001'>all</z:hpo> patients experienced severe BM toxicity </plain></SENT>
<SENT sid="7" pm="."><plain>With a median follow-up of 66 months (range, 6-165 months), 11 patients relapsed </plain></SENT>
<SENT sid="8" pm="."><plain>The estimate 2-year overall survival and disease-free survival were 47.1% (95% CI, 34-59.1) and 67.8% (95% CI, 51-80), respectively </plain></SENT>
<SENT sid="9" pm="."><plain>We identified 2 poor prognosis factors: low CD4 count and ECOG more than 2 </plain></SENT>
<SENT sid="10" pm="."><plain>Patients with 0 or 1 factor had good outcome (2-year survival: 60%) contrasting with patients with 2 factors (2-year survival: 12%) </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude that LMB86 regimen is highly effective in advanced HIV-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and should be proposed for patients with CD4 count higher than 200 x 10(6)/L or ECOG of 2 or less </plain></SENT>
</text></document>